Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Search
  1. ESMO
  2. Guidelines

ESMO-Magnitude of Clinical Benefit Scale

ESMO MCBS 1000x250

What is the ESMO-MCBS?

The ESMO-MCBS facilitates improved decision-making regarding the value of anti-cancer therapies, promotes accessibility and reduces iniquity of access to high value cancer treatments.

Read more

Evaluation Forms and Instructions

Check out the forms and instructions of the scale and download them for your easy use.

Read more
ESMO-MCBS Scorecards 1000x750px

Scorecards

Discover the cancer medicines that have been scored and published by ESMO using the online filter, which allows you to filter either by Agent, Tumour or Score in the curative or non-curative setting

Read more

Dissemination and applicability of the ESMO-MCBS

Keep up to date with the latest ESMO publications and Congress presentations of the ESMO-MCBS and make sure you don’t miss anything!

  1. Special Session, ESMO-MCBS in perspective
  2. Poster Discussion Session - Public health policy, 1562PD - Magnitude of Clinical Benefit of Cancer Drugs Approved Based on Single-Arm Trials (SAT) by the US Food and Drug Administration (FDA)
  3. Poster Discussion Session - Public health policy, 1563PD - Magnitude of Clinical Benefit in Trials Supporting US Food and Drug Administration (FDA) Accelerated Approval (AA) and European Medicines Agency (EMA) Conditional Marketing Authorisation (CMA) and Subsequent Trials Supporting Conversion to Full Approval
  4. Poster Discussion Session - Public health policy, 1564PD - Magnitude of Clinical Benefit of Trials Supporting US Food and Drug Administration (FDA) Approval of Breakthrough and Non-breakthrough Drugs
  5. Poster Discussion Session - Public health policy, 1565PD - Time to access to novel anticancer therapies in Slovenia in view of the ESMO-MCBS scores
  6. Proffered paper session - Public health policy, 1555O_PR - Magnitude of clinical benefit of cancer drugs and time to health technology assessment (HTA) decisions in Europe
  1. 1441PD - Magnitude of clinical benefit of randomized controlled trials supporting US Food and Drug Administration approval of drugs for solid tumours
  2. Special Session, Cost value and assessment tools of therapies in modern oncology
  3. Proffered Paper Session: 1435O_PR - Comparison of the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) in Clinical Trials Supporting US Food and Drug Administration (FDA) Approval of Orphan vs. Non-orphan Drugs.
  4. Proffered Paper Session: 1436O_PR - How to assess a cancer therapy? Feedback from the French HTA body on the ESMO-MCBS
  5. Proffered Paper Session: 1437O_PR - Clinical Benefit of Randomized Controlled Trials (RCT) Supporting US Food and Drug Administration (FDA) Conversion from Accelerated to Full Approval
  1. ESMO Society Session (28 September), where Elisabeth de Vries presented the scale and Alexandru Eniu  explained how the scale is applied using the data from the ESMO Anti-Neoplastic Medicines Surveys.
  2. ESO Society Session: ‘Is innovation Affordable?’, 26 September
  3. Oncopolicy Forum: Inequalities in Treatment Outcomes, 27 September
  4. Special Session: Evaluating Clinical Benefit of Cancer Drugs Across Tumours, 28 September

ASCO 2015: ESMO-MCBS was launched at the ESMO/ASCO Joint Session during ASCO 2015

In this podcast, Professor Martine Piccart (Scientific Director of the Institut Jules Bordet, Universite Libre de Bruxelles, Belgium) shares valuable insights on the work that has been done in the field of access to essential cancer medicines by the ESMO-Magnitude of Clinical Benefit Scale Working Group

For further information about the ESMO-MCBS, please send an email to mcbs@esmo.org

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.